Am J Transplant, Volume 19, Suppl 3 Archives - Page 133 of 214 - ATC Abstracts

2019 American Transplant Congress
Intra-Abdominal Hypertension in Simultaneous Pancreas-Kidney Transplantation
T. Ameen, G. Papadakis, R. Punjala, N. Karydis
Nephrology and Transplantation, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
*Purpose: There have been several reports of raised intra-abdominal pressure (IAP) in solid organ transplantation, including life threatening abdominal compartment syndrome requiring decompressive laparotomy. In…
2019 American Transplant Congress
Use of Belatacept in Pancreas Transplantation
P. D. Uva, A. Quevedo, J. Roses, R. Pilotti, E. Chuluyan, D. Casadei
Kidney/Pancreas Transplantation, ITAC - Nephrology, Buenos Aires, Argentina
*Purpose: To review our experience with Belatacept in pancreas transplantation*Methods: Retrospective review including all patients receiving Belatacept after pancreas transplantation. Main objective is to review…
2019 American Transplant Congress
Determining the Role of Insurance Coverage at the Time of Renal Transplantation as a Predictor of Medication Misadventure
D. Wilkerson, P. Klem
Pharmacy, University of Colorado Skaggs School of Pharmacy, Aurora, CO
*Purpose: To determine if patients who receive financial assistance through the American Kidney Fund (AKF) for health care premiums at the time of transplant are…
2019 American Transplant Congress
Impact of Everolimus on Secondary Nonmelanoma Skin Cancer Prevention in Solid Organ Transplant Recipients
B. Clark¹, D. D. Ramirez¹, A. Carlson¹, B. Sirandas¹, C. Truax¹, L. Smith¹, I. Hall²
¹Solid Organ Transplant, University of Utah Health, Salt Lake City, UT, ²Nephrology and Hypertension, University of Utah Health, Salt Lake City, UT
*Purpose: Over half of solid organ transplant recipients (SOTR) develop nonmelanoma skin cancers (NMSC) and up to 80% experience recurrence. Many immunosuppressive drugs are known…
2019 American Transplant Congress
A Multicenter Study Of mTOR Inhibitor Use In Intestine And Multivisceral Transplantation
M. C. Segovia¹, A. Mavis¹, J. Boike², Y. Patel¹, T. Schiano³, S. Jafri⁴
¹Duke, Durham, NC, ²NWU, Chicago, IL, ³Mt Sinai, NY, NY, ⁴Henry Ford, Detroit, MI
*Purpose: Review the frequency, indications and outcomes of the use of mTOR inhibitors (mTOR) after intestine (IT) and multivisceral transplantation (MVT) at multiple centers in…
2019 American Transplant Congress
Comparison of Simultaneous Pancreas kidney Transplantation to Kidney Transplantation Alone for Type 2 Diabetes with End Stage Renal Disease
Y. Fu, Z. Shen
Kidney&Pancreas Transplant, Tianjin First Center Hospital, Tianjin, China
*Purpose: To compare the clinic outcomes of simultaneous pancreas-kidney transplantation (SPK) with kidney transplantation alone (KTA) in Type 2 Diabetes patients with ESRD.*Methods: 97 type…
2019 American Transplant Congress
Human Neutrophil Function against Pathogens in Solid Organ and Stem Cell Transplant Recipients
N. Barros, N. Alexander, Z. Dagher, S. Knooihuizen, A. Viens, A. R. Hopke, D. Irimia, M. K. Mansour
Transplant Infectious Diseases, Massachusetts General Hospital, Boston, MA
*Purpose: The effects of solid organ (SOT) and allogeneic stem cell transplantation (SCT) on the neutrophil function is not well described. In this study, we…
2019 American Transplant Congress
Restrictive Medicaid Policies Reduce Access to Liver Transplant for Alcohol-Associated Liver Disease
B. P. Lee, V. Eric, P. Mark, J. Dodge, N. Terrault
UCSF, SF, CA
*Purpose: Medicaid policies requiring specific documentation of abstinence (e.g. 6 months) and/or rehabilitation for financial coverage of liver transplant (LT) for alcohol-associated liver disease (ALD)…
2019 American Transplant Congress
Costimulatory Blockade and Allo-Specific Treg Therapy for Liver Transplant Recipients: Preclinical Data
L. Contreras-Ruiz¹, K. Shimozawa², R. Zhang¹, L. Turka³, J. F. Markmann³, E. C. Guinan²
¹Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, ²Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, ³Center of Transplantation Sciences, Massachussetts General Hosp., Boston, MA
*Purpose: Adoptive transfer of ex vivo generated donor-specific regulatory T cells (Treg) by using CD28/B7 costimulatory blockade (CSB) to induce transplant (TX) tolerance and minimize…
2019 American Transplant Congress
A Novel Method for Ex Vivo Treg Expansion via Human iNKT Cell Activation
R. Ishii¹, I. Masako¹, H. Katsumata¹, T. Kanzawa¹, T. Yamakawa¹, H. Ishigooka¹, T. Hirai¹, K. Saiga¹, M. Okumi¹, Y. Ishii², K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Vaccine Innovation Laboratory RIKEN Cluster for Science, Technology and Innovation Hub (RCSTI), Kanagawa, Japan
*Purpose: Tregs play a critical role in immune tolerance. If Tregs can be administered to patients suffering from immune disorders, most therapies employing existing immunosuppressants…